- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| Mo | Viatris sells Biocon Biologics stake for $815 million in cash and equity deal | 21 | Seeking Alpha | ||
| Sa | Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln | 580 | AFX News | NEW DELHI (dpa-AFX) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the... ► Artikel lesen | |
| Sa | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::ANALYST CALL INTIMATION SUBMITTED BY BIOCON LIMITED | 3 | SGX Company Announcements | ||
| Sa | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 3 | SGX Company Announcements | ||
| BIOCON BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Sa | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::OUTCOME OF BOARD MEETING OF BIOCON LIMITED | 2 | SGX Company Announcements | ||
| 02.12. | Biocon Biologics settles with Amgen to launch Denosumab Biosimilars in Europe, rest of the world | 10 | ZEE Business | ||
| 02.12. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 27.11. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::COMPANY STATEMENT | 8 | SGX Company Announcements | ||
| 12.11. | BIOCON BIOLOGICS GLOBAL PLC: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::SECOND QUARTER AND/OR HALF YEARLY RESULTS | 3 | SGX Company Announcements | ||
| 11.11. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements | ||
| 23.10. | Biocon Biologics Receives Health Canada Approval for Yesintek and Yesintek I.V. (ustekinumab), a Biosimilar to Stelara | 4 | CNW | ||
| 23.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 16.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 2 | SGX Company Announcements | ||
| 02.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::STOCK EXCHANGE DISCLOSURE BY BIOCON LIMITED | 5 | SGX Company Announcements | ||
| 01.10. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 5 | SGX Company Announcements | ||
| 18.09. | Biocon Biologics' Yesafili (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases | 2 | CNW | ||
| 17.09. | Biocon Biologics Says FDA Approves Bosaya And Aukelso As Denosumab Biosimilars | 2 | RTTNews | ||
| 17.09. | Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya and Aukelso, Denosumab Biosimilars | 1.009 | PR Newswire | BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary... ► Artikel lesen | |
| 17.09. | BIOCON BIOLOGICS GLOBAL PLC: GENERAL ANNOUNCEMENT::PRESS RELEASE | 1 | SGX Company Announcements |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | -2,18 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | +0,99 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | +2,18 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | +2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| QIAGEN | 38,605 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | +0,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | -3,70 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | -1,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | +3,79 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | -0,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | -7,25 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright |
BIOCON BIOLOGICS GLOBAL PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,05 % bei einem Aktienkurs von 99,76 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCON BIOLOGICS GLOBAL PLC finden Sie auf Wallstreet Online.